SCHEMBL23704817

SCHEMBL23704817

COc1cc(-c2cccc(-c3csc(NC(=O)CNC(=O)c4cccc(C(C)(C)CNC(=O)O)c4)n3)c2)ccn1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 7/20 0.51
▸ ROCK1 Q13464 5/20 0.44
▸ ALDH1A1 P00352 3/20 0.42
▸ MAPT P10636 2/20 0.42
▸ THRB P10828 1/20 0.42
▸ WNT3A P56704 4/20 0.42
▸ PRKACA P17612 1/20 0.42
▸ KMT2A Q03164 3/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ NPC1 O15118 2/20 0.40
▸ RAB9A P51151 2/20 0.40
▸ HPGD P15428 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ CASP3 P42574 1/20 0.40
▸ SENP7 Q9BQF6 1/20 0.40
▸ CCR2 P41597 1/20 0.39
▸ KCNH2 Q12809 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23714972 0.92 CYP3A4 (0.49) CYP3A4ROCK1ALDH1A1MAPTTHRB
SCHEMBL30058825 0.92 CYP3A4 (0.49) CYP3A4ROCK1ALDH1A1MAPTTHRB
SCHEMBL23704897 0.91 CYP3A4 (0.53) CYP3A4ROCK1ALDH1A1MAPTTHRB
SCHEMBL30058857 0.91 CYP3A4 (0.53) CYP3A4ROCK1ALDH1A1MAPTTHRB
SCHEMBL23705382 0.89 CYP3A4 (0.48) CYP3A4ROCK1MAPTWNT3APRKACA
SCHEMBL23704938 0.89 MAPT (0.46) CYP3A4ROCK1ALDH1A1MAPTTHRB
SCHEMBL28939613 0.89 CYP3A4 (0.51) CYP3A4ROCK1ALDH1A1MAPTTHRB
SCHEMBL23704953 0.89 SYK (0.43) MAPTWNT3AKMT2AMEN1
SCHEMBL23704883 0.89 WNT3A (0.42) CYP3A4ROCK1MAPTWNT3ASMN1; SMN2
SCHEMBL23704915 0.88 WNT3A (0.43) CYP3A4ROCK1ALDH1A1MAPTWNT3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 — — US disclosed
EP-4096657-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2022-12-07 — — EP disclosed
WO-2021155316-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2021-08-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230149414-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB CYP3A4 3718/4885ROCK1 4248/4885ALDH1A1 2571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback